SCHEMBL3974312

SCHEMBL3974312

Cc1ccc2nc(-c3ccc(Br)cc3)nc(N(C)C3CCCCC3)c2c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.53
GBA1 P04062 8/20 0.50
SMN1; SMN2 Q16637 2/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
MAPT P10636 3/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
MCL1 Q07820 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
TP53 P04637 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
LATS1 O95835 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3977126 0.88 GBA1 (0.49) POLBGBA1SMN1; SMN2TSHRMAPK1
SCHEMBL3976899 0.82 SPIN1 (0.49) POLBGBA1SMN1; SMN2TSHRMAPK1
SCHEMBL4863775 0.75 GBA1 (0.80) POLBGBA1SMN1; SMN2TSHRMAPK1
SCHEMBL3979617 0.75 POLB (0.50) POLBSMN1; SMN2TSHRMAPK1MAPT
SCHEMBL3979623 0.75 POLB (0.37) POLBSMN1; SMN2TSHRMAPK1MAPT
SCHEMBL3974310 0.74 GBA1 (0.51) POLBGBA1KMT2AMEN1
SCHEMBL6671464 0.74 NPC1 (0.38) SMN1; SMN2MAPK1MAPTKMT2AALDH1A1
SCHEMBL4867366 0.74 GBA1 (0.79) POLBGBA1SMN1; SMN2TSHRMAPK1
SCHEMBL3973245 0.74 PDE5A (0.62) POLBGBA1SMN1; SMN2TSHRMAPT
SCHEMBL3978935 0.74 LATS1 (0.52) POLBGBA1MAPK1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547702-B2 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2009-06-16 US disclosed
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents ORTHO-MCNEIL PHARMACEUTICALS, INC. 2006-01-26 US disclosed
WO-2004030672-A1 USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS MERCK PATENT GMBH (DE) 2004-04-15 WO disclosed
CN-1474815-A 4-amino-quinazolines Ĭ��ר���ɷ����޹�˾ 2004-02-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents SERPINA3, APOL1, MGAT3 POLB 4723/4885GBA1 52/4885SMN1; SMN2 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.